학제간연구 | Interdisciplinary Studies in Gambling | 跨学科研究
- date : 2015-05-20 01:10|hit : 191
-
- Review] On the potential of thioredoxin reductase inhibitors for cancer therapy
-
DocNo of ILP: 4550
Doc. Type: Review
Title: On the potential of thioredoxin reductase inhibitors for cancer therapy
Authors: Urig, S; Becker, K
Full Name of Authors: Urig, Sabine; Becker, Katja
Keywords by Author: cancer; chemotherapy; inhibitor; redox sensitivity; thioredoxin reductase
Keywords Plus: PLATINUM ANTICANCER DRUGS; CISPLATIN-ALBUMIN COMPLEX; GLUTATHIONE-S-TRANSFERASE; APOPTOSIS-INDUCING LIGAND; CELL GROWTH-INHIBITION; WHOLE-BRAIN RADIATION; IN-VITRO; MAMMALIAN THIOREDOXIN; GLIOBLASTOMA-MULTIFORME; MOTEXAFIN GADOLINIUM
Abstract: Thioredoxin reductase (TrxR)-as part of a major thiol regulating system-allows redox metabolism to adjust to cellular requirements. Therefore, changes at the redox level reflect as a pars pro toto changes concerning the entire cell. Three different TrxR isoenzymes, TrxR1 as cytosolic, TrxR2 as mitochondrial, and TrxR3 as testis-specific thiol regulator are known. All three enzymes contain a reactive and solvent accessible selenocysteine residue which is located on a flexible C-terminal arm of the protein. This selenocysteine is essentially involved in the catalytic cycle of TrxR and thus represents an attractive binding site for inhibitors. Many tumor cells have elevated TrxR levels and TrxR has been shown to play a major role in drug resistance. Inhibition of TrxR and its related redox reactions may thus contribute to a successful single, combinatory or adjuvant cancer therapy. A great number of effective natural and synthetic TrxR inhibitors are now available possessing antitumor potential ranging from induction of oxidative stress to cell cycle arrest and apoptosis. This article summarizes the present knowledge on the potential of TrxR inhibitors and TrxR as anticancer drug target. (c) 2006 Elsevier Ltd. All rights reserved.
Cate of OECD: Clinical medicine
Year of Publication: 2006
Business Area: other
Detail Business: medicine & science
Country: England
Study Area: terminal, terminal, drug, cancer
Name of Journal: SEMINARS IN CANCER BIOLOGY
Language: English
Country of Authors: Univ Giessen, Interdisciplinary Res Ctr, IFZ, D-35392 Giessen, Germany
Press Adress: Becker, K (reprint author), Univ Giessen, Interdisciplinary Res Ctr, IFZ, D-35392 Giessen, Germany.
Email Address: becker.katja@gmx.de
Citaion:
Funding:
Lists of Citation: Ahmadi R, 2006, FREE RADICAL BIO MED, V40, P763, DOI 10.1016/j.freeradbiomed.2005.09.031; Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; Arner ESJ, 1999, BIOFACTORS, V10, P219; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Baker A, 1997, CANCER RES, V57, P5162; Balendiran GK, 2004, CELL BIOCHEM FUNCT, V22, P343, DOI 10.1002/cbf.1149; Bauer H, 2003, J BIOL CHEM, V278, P33020, DOI 10.1074/jbc.M303762200; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i; Belani CP, 2004, SEMIN ONCOL, V31, P25, DOI 10.1053/j.seminoncol.2004.11.005; Beltinger C, 2002, CANCER GENE THER, V9, P372, DOI 10.1038/sj/cgt/7700448; Berggren M, 1996, ANTICANCER RES, V16, P3459; Biot C, 2003, REDOX REP, V8, P280, DOI 10.1179/135100003225002916; Birner P, 2002, ONCOL REP, V9, P703; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; Brandt W, 2005, CHEMBIOCHEM, V6, P386, DOI 10.1002/cbic.200400276; BRITTEN RA, 1992, INT J RADIAT ONCOL, V24, P527; Cenas N, 2006, J BIOL CHEM, V281, P5593, DOI 10.1074/jbc.M511972200; Cenas N, 2004, J BIOL CHEM, V279, P2583, DOI 10.1074/jbc.M310292200; Chen Xiang, 1998, Chemico-Biological Interactions, V111-112, P263, DOI 10.1016/S0009-2797(97)00166-X; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Cornish-Bowden A, 2004, FUNDAMENTALS ENZYME; Coronnello M, 2005, J MED CHEM, V48, P6761, DOI 10.1021/jm050493o; Cortes A, 2001, BIOCHEM J, V357, P263, DOI 10.1042/0264-6021:3570263; DALU Y, 2006, MED HYPOTHESES, V66, P45; Denicourt C, 2004, SCIENCE, V305, P1411, DOI 10.1126/science.1102974; Deponte M, 2005, J BIOL CHEM, V280, P20628, DOI 10.1074/jbc.M412519200; Engman L, 2003, BIOORGAN MED CHEM, V11, P5091, DOI 10.1016/j.bmc.2003.08.021; Engman L, 2003, ANTI-CANCER DRUG, V14, P153, DOI 10.1097/01.cad.0000054522.51553.fd; Engman L, 2000, ANTI-CANCER DRUG DES, V15, P323; FANG J, 2005, J BIOL CHEM; Filomeni G, 2005, ANTIOXID REDOX SIGN, V7, P446, DOI 10.1089/ars.2005.7.446; Friesen C, 2004, CELL DEATH DIFFER, V11, pS73, DOI 10.1038/sj.cdd.4401431; Fuertes M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P539, DOI 10.2174/1568011023353958; Fuertes MA, 2003, CHEM REV, V103, P645, DOI 10.1021/cr020010d; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Galanski M, 2003, CURR PHARM DESIGN, V9, P2078, DOI 10.2174/1381612033454180; Gallegos A, 1997, CANCER RES, V57, P4965; Gan L, 2005, J CELL BIOCHEM, V96, P653, DOI 10.1002/jcb.20585; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gasdaska JR, 1996, GENOMICS, V37, P257, DOI 10.1006/geno.1996.0554; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Giovagnini L, 2005, J MED CHEM, V48, P1588, DOI 10.1021/jm049191x; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gliniak B, 1999, CANCER RES, V59, P6153; Gromer S, 1998, BIOCHEM J, V332, P591; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Haapasalo H, 2003, BRAIN PATHOL, V13, P155; Hall MD, 2004, J INORG BIOCHEM, V98, P1614, DOI 10.1016/j.jinorgbio.2004.05.017; Hall MD, 2004, MET IONS BIOL SYST, V42, P297; HALL MD, 2006, J STRUCT BIOL; Hashemy SI, 2006, J BIOL CHEM, V281, P10691, DOI 10.1074/jbc.M511373200; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; HOLDING JD, 1992, BRIT J CLIN PHARMACO, V33, P75; Hooper M L, 1994, J Cell Sci Suppl, V18, P13; Irmler A., 2002, FLAVINS FLAVOPROTEIN, P803; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Jansen BAJ, 2002, J INORG BIOCHEM, V89, P197, DOI 10.1016/S0162-0134(02)00381-1; Jendrossek V, 2003, EXPERT OPIN INV DRUG, V12, P1899, DOI 10.1517/13543784.12.12.1899; Jeremias I, 2004, ACTA NEUROCHIR, V146, P721, DOI 10.1007/s00701-004-0286-4; Jiang C, 1999, MOL CARCINOGEN, V26, P213, DOI 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO;2-Z; Jonsson-Videsater K, 2004, BIOCHEM PHARMACOL, V67, P513, DOI 10.1016/j.bcp.2003.09.021; Kahlos K, 2001, INT J CANCER, V95, P198, DOI 10.1002/1097-0215(20010520)95:3<198::AID-IJC1034>3.0.CO;2-F; Kaludjerovic GN, 2005, INT J CANCER, V116, P479, DOI 10.1002/ijc.21080; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P1373, DOI 10.1517/13543784.9.6.1373; Kelland LR, 2000, DRUG RESIST UPDATE, V3, P139, DOI 10.1054/drup.2000.0132; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Kurosaki H, 2003, BIOORG MED CHEM LETT, V13, P825, DOI 10.1016/S0960-894X(03)00012-X; Lechner S, 2003, LAB INVEST, V83, P1321, DOI 10.1097/01.LAB.0000085189.47968.F8; Lincoln DT, 2003, ANTICANCER RES, V23, P2425; Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310; Lu JX, 2001, NUTR CANCER, V40, P64, DOI 10.1207/S15327914NC401_12; Ma S, 2003, J AM SOC MASS SPECTR, V14, P593, DOI 10.1016/S1044-0305(03)00141-7; Marcon G, 2002, J MED CHEM, V45, P1672, DOI 10.1021/jm010997w; MATSUMURA Y, 1986, CANCER RES, V46, P6387; McNaughton M, 2004, J MED CHEM, V47, P233, DOI 10.1021/jm030916r; Mehta MP, 2002, J CLIN ONCOL, V20, P3445, DOI 10.1200/JCO.2002.07.500; Mellor HR, 2005, BIOCHEM PHARMACOL, V70, P1137, DOI 10.1016/j.bcp.2005.07.016; Messori L, 2004, BIOORGAN MED CHEM, V12, P6039, DOI 10.1016/j.bmc.2004.09.014; Meyers CA, 2004, J CLIN ONCOL, V22, P157, DOI 10.1200/JCO.2004.05.128; Millet R, 2005, J MED CHEM, V48, P7024, DOI 10.1021/jm0502561; Miranda-Vizuete A, 2004, ANTIOXID REDOX SIGN, V6, P25, DOI 10.1089/152308604771978327; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Mohler JL, 2002, PROSTATE, V51, P247, DOI 10.1002/pros.10086; Moos PJ, 2004, CARCINOGENESIS, V25, P1611, DOI 10.1093/carcin/bgh163; Mukherjee A, 2005, BRIT J CANCER, V92, P350, DOI 10.1038/sj.bjc.6602338; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nagane M, 2000, CANCER RES, V60, P847; Nalvarte I, 2004, J BIOL CHEM, V279, P54510, DOI 10.1074/jbc.M408494200; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; OMATA Y, 2006, TOXICOL IN VITRO; Pallis M, 2003, BIOCHEM PHARMACOL, V66, P1695, DOI 10.1016/S0006-2952(03)000471-4; Parney IF, 2003, CANCER J, V9, P149, DOI 10.1097/00130404-200305000-00003; PASINI A, 1987, ANGEW CHEM INT EDIT, V26, P615, DOI 10.1002/anie.198706151; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Rieger J, 1999, NEUROL PSYCHIAT BR, V7, P37; Rigobello MP, 2006, BIOCHEM BIOPH RES CO, V343, P873, DOI 10.1016/j.bbrc.2006.03.050; Rigobello MP, 2005, ARCH BIOCHEM BIOPHYS, V441, P112, DOI 10.1016/j.abb.2005.07.007; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; Rigobello MP, 2005, FREE RADICAL RES, V39, P687, DOI 10.1080/10715760500135391; Rigobello MP, 2004, J INORG BIOCHEM, V98, P1634, DOI 10.1016/j.jinorgbio.2004.04.020; Rigobello MP, 2002, BRIT J PHARMACOL, V136, P1162, DOI 10.1038/sj.bjp.0704823; Ronconi L, 2006, J MED CHEM, V49, P1648, DOI 10.1021/jm0509288; Ronconi L, 2005, INORG CHEM, V44, P1867, DOI 10.1021/ic048260v; Rooseboom M, 2001, CHEM RES TOXICOL, V14, P127, DOI 10.1021/tx0001326; Ross SA, 2000, ANTI-CANCER DRUG DES, V15, P431; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; ROZELL B, 1988, EUR J CELL BIOL, V46, P470; Ruefli AA, 2001, DRUG DEVELOP RES, V52, P549; Rundlof AK, 2004, ANTIOXID REDOX SIGN, V6, P41, DOI 10.1089/152308604771978336; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Rundlof AK, 2000, BIOCHEM J, V347, P661, DOI 10.1042/0264-6021:3470661; RUSSO A, 1986, CANCER RES, V46, P2845; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Sasada T, 1999, FREE RADICAL BIO MED, V27, P504, DOI 10.1016/S0891-5849(99)00101-X; SCHALLREUTER KU, 1990, BIOCHIM BIOPHYS ACTA, V1054, P14, DOI 10.1016/0167-4889(90)90199-N; Schatzschneider U, 2006, ANGEW CHEM INT EDIT, V45, P1504, DOI 10.1002/anie.200504604; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Seemann S, 2005, ONCOGENE, V24, P3853, DOI 10.1038/sj.onc.1208549; Senturker S, 2002, ARCH BIOCHEM BIOPHYS, V397, P262, DOI 10.1006/abbi.2001.2681; Senzer N, 2005, EXPERT OPIN THER TAR, V9, P1189, DOI 10.1517/14728222.9.6.1189; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Shen YQ, 2005, EXPERT OPIN BIOL TH, V5, P1427, DOI 10.1517/14712598.5.11.1427; Shi CJ, 2003, BIOCHEM BIOPH RES CO, V309, P578, DOI 10.1016/j.bbrc.2003.08.032; Smart DDK, 2004, CANCER RES, V64, P6716, DOI 10.1158/0008-5472.CAN-03-3990; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Streicher KL, 2004, NUTR CANCER, V50, P221, DOI 10.1207/s15327914nc5002_13; Su D, 2004, BIOCHEMISTRY-US, V43, P12177, DOI 10.1021/bi048478t; Su D, 2005, J BIOL CHEM, V280, P26491, DOI 10.1074/jbc.M503638200; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2001, J BIOL CHEM, V276, P3106, DOI 10.1074/jbc.M004750200; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Sun QA, 2005, BIOCHEMISTRY-US, V44, P14528, DOI 10.1021/bi051321w; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; Turunen N, 2004, APMIS, V112, P123, DOI 10.1111/j.1600-0463.2004.apm1120207.x; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Urig S, 2006, ANGEW CHEM INT EDIT, V45, P1881, DOI 10.1002/anie.200502756; URIG S, 2005, FLAVINS FLAVOPROTEIN, P877; VREEBURG GCM, 1992, J LARYNGOL OTOL, V106, P832, DOI 10.1017/S0022215100121012; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wen Patrick Y, 2004, Curr Neurol Neurosci Rep, V4, P218, DOI 10.1007/s11910-004-0042-4; Westphal M, 2003, ACT NEUR S, V88, P61; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Winter S, 2000, J NEUROL SCI, V179, P115, DOI 10.1016/S0022-510X(00)00392-0; Wipf P, 2005, ORG BIOMOL CHEM, V3, P3880, DOI 10.1039/b510718k; Wipf P, 2004, ORG BIOMOL CHEM, V2, P1651, DOI 10.1039/b402431a; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; YOKOMIZO A, 1995, CANCER RES, V55, P4293; Yoo MH, 2006, J BIOL CHEM, V281, P13005, DOI 10.1074/jbc.C600012200; Young SW, 1996, P NATL ACAD SCI USA, V93, P6610, DOI 10.1073/pnas.93.13.6610; Zhao F, 2006, CANCER LETT, V236, P46, DOI 10.1016/j.canlet.2005.05.010; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200; Zorbas H, 2005, CHEMBIOCHEM, V6, P1157, DOI 10.1002/cbic.200400427; Zou J, 2000, ANGEW CHEM INT EDIT, V39, P2931, DOI 10.1002/1521-3773(20000818)39:16<2931::AID-ANIE2931>3.0.CO;2-W
Number of Citaion: 169
Publication: ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
City of Publication: LONDON
Address of Publication: 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
ISSN: 1044-579X
29-Character Source Abbreviation: SEMIN CANCER BIOL
ISO Source Abbreviation: Semin. Cancer Biol.
Volume: 16
Version: 6
Start of File: 452
End of File: 465
DOI: 10.1016/j.semcancer.2006.09.004
Number of Pages: 14
Web of Science Category: Oncology
Subject Category: Oncology
Document Delivery Number: 121MK
Unique Article Identifier: WOS:000243161500006
- reply : 0
-
- list
-
- prev
- next